Evaluation of low-dose aspirin for primary prevention of ischemic stroke among patients with diabetes: A retrospective cohort study

Diabetology and Metabolic Syndrome

Volumn 7, Issue 1, 2015, Pages

  Kim, Ye Jee ^a   Choi, Nam Kyong ^b   Kim, Mi Sook ^b   Lee, Joongyub ^b   Chang, Yoosoo ^c   Seong, Jong Mi ^a   Jung, Sun Young ^a   Shin, Ju Young ^a   Park, Ji Eun ^b,d   Park, Byung Joo ^a,b,d  

^a Korea Institute of Drug Safety and Risk Management   (South Korea)

^b Seoul National University   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d National Evidence Based Healthcare Collaborating Agency   (South Korea)

Author keywords

Aspirin; Diabetes mellitus; Health insurance claims database; Ischemic stroke; Retrospective cohort study

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DYSLIPIDEMIA; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NATIONAL HEALTH INSURANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VERY ELDERLY;

EID: 84924163322     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/s13098-015-0002-y     Document Type: Article

References (34)

1. Preventive US. Services Task Force: Aspirin for the prevention of cardiovascular disease: U. S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150(6):396-404.
2. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care. 2003;26(12):3264-72.
3. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh: The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. Brit Med J. 2008;337:a1840.
4. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300(18):2134-41.
5. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-60.
6. De Berardis G, Sacco M, Strippoli GFM, Pellegrini F, Graziano G, Tognoni G, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. Brit Med J. 2009;339:b4531.
7. American Diabetes Association. Standards of Medical Care in Diabetes-2012. Diabetes Care. 2012;35(1):S11-63.
8. Kim J, Kim H, Kim H, Min JW, Park SW, Park IB, et al. Current status of the continuity of ambulatory diabetes care and its impact on health outcomes and medical cost in Korea using National Health Insurance database. J Korean Diabetes Assoc. 2006;30(5):377-87.
9. Kwon S. Thirty years of national health insurance in South Korea: lessons for achieving universal health care coverage. Health Policy Plan. 2009;24(1):63-71.
10. Seeger JD, Walker AM, Williams PL, Saperia GM, Sacks FM. A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction. Am J Cardiol. 2003;92(12):1447-51.
11. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11(7):449-57.
12. D'Agostino Jr RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265-81.
13. Parson LS. Reducing bias in a propensity score matching techniques. In SAS SUGI 26, 2001:214-226. http://www2.sas.com/proceedings/sugi26/p214-26.pdf
14. Austin PC. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med. 2008;27(12):2037-49.
15. Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, Luzak B, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res. 2004;113:101-13.
16. Takahashi S, Ushida M, Komine R, Shimizu A, Uchida T, Ishihara H, et al. Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. Thromb Res. 2007;119:517-24.
17. Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia. 2008;51(3):385-90.
18. Pulcinelli FM, Biasucci LM, Riondino S, Giubilato S, Leo A, Di Renzo L, et al. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. Eur Heart J. 2009;30:1279-86.
19. De Berardis G, Lucisano G, D'Ettorre A, Pellegrini F, Lepore V, Tognoni G, et al. Association of Aspirin Use With Major Bleeding in Patients With and Without Diabetes. JAMA. 2012;307(21):2286-94.
20. Investigators ETDRS. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report
21. ETDRS Investigators. JAMA. 1992;268(10):1292-300.
22. Henry P, Vermillet A, Boval B, Guyetand C, Petroni T, Dillinger JG, et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemostasis. 2011;105 (2) 336-44.
23. Leung WY, So WY, Stewart D, Lui A, Tong PC, Ko GT, et al. Lack of benefits for prevention of cardiovascular disease with aspirin therapy in type 2 diabetic patients-a longitudinal observational study. Cardiovasc Diabetol. 2009;8:57.
24. Welin L, Wilhelmsen L, Bjornberg A, Oden A. Aspirin increases mortality in diabetic patients without cardiovascular disease: a Swedish record linkage study. Pharmacoepidemiol Drug Saf. 2009;18(12):1143-9.
25. Sasso FC, Marfella R, Pagano A, Porta G, Signoriello G, Lascar N, et al. Lack of effect of aspirin in primary CV prevention in type 2 diabetic patients with nephropathy: results from 8 years follow-up of NID-2 study. Acta Diabetol 2014 Aug. 11. [Epub ahead of print]
26. Ong G, Davis TME, Davis WA. Aspirin Is Associated With Reduced Cardiovascular and All-Cause Mortality in Type 2 Diabetes in a Primary Prevention Setting - The Fremantle Diabetes Study. Diabetes Care. 2010;33(2):317-21.
27. Psaty BM, Siscovick DS. Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction. JAMA. 2010;304:897-8.
28. Park BJ, Sung JH, Park KD, Seo SW, Kim SW. Report of the evaluation for validity of discharged diagnoses in Korean Health Insurance database. Seoul: Seoul National University; 2003.
29. Kim JY. Strategies to enhance the use of National Health Insurance Claims Database in generating health statistics. Seoul: Health Insurance Review and Assessment Services; 2005.
30. Task Force Team for Basic Statistical Study of Korean Diabetes Mellitus of Korean Diabetes Association, Park IB, Kim J, Kim DJ, Chung CH, Oh JY, et al. Diabetes epidemics in Korea: reappraise nationwide survey of diabetes "diabetes in Korea 2007". Diabetes Metab J. 2013;37(4):233-9.
31. Park IB, Kim DJ, Kim J, Kim H, Kim H, Min KW, et al. Current status of aspirin user in Korean Diabetic Patients Using Korean Health Insurance Database. J Kor Diabetes Assoc. 2006;30(5):363-71.
32. American Diabetes Association. Standards of Medical Care in Diabetes-2015. 8. Cardiovascular Disease and Risk Management. Diabetes Care. 2015;38 Suppl 1:S49-57.
33. De Berardis G, Sacco M, Evangelista V, Filippi A, Giorda CB, Tognoni G, et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials. 2007;8:21.
34. ASCEND Investigators. A Study of Cardiovascular Events iN Diabetes. Current Controlled Trials. 2005. http://clinicaltrials.gov/ct2/show/NCT00135226